Testing SSS59 for advanced malignant tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label phase I study evaluates the safety, pharmacokinetics, and antitumor activity of SSS59 as a monotherapy in patients with advanced malignancies. The study is divided into four parts: dose escalation and extension for different administration schedules, and an indication extension for specific types of advanced tumors. Participants will receive SSS59 to determine its effectiveness and safety profile in treating their conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically and/or cytologically documented local advanced or recurrent or metastatic malignancies.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
* Expected survival \>3 months.
* Signed informed consent form.
* Must have adequate organ function.

Exclusion Criteria:

* Any remaining AEs \> grade 1 from prior anti-tumor treatment as per CTCAE v5. 0, with exception of hair loss and fatigue.
* Pregnant or nursing women or women/men who are ready to give birth.
* symptomatic central nervous system metastasis.
* Allergy to other antibody drugs or any excipients in the study drugs.
* Underwent major surgery within 4 weeks prior to first dosing.
* The patient is participating in another clinical study, unless it is an observational (non-intervention) clinical study or a follow-up period of an intervention study.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Where it's running

• Shanghai First People's Hospital
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Qi Li, MD
• Email: Leeqi2001@hotmail.com
• Phone: 86+13818207333

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Prognosis and molecular features of malignant tumors in adults

  This study tests how key molecular features relate to outcomes in adults with malignant tumors treated at a single hospital.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT07622667

• 68Ga-FL-031 PET for diagnosing and staging cancer

  This project will test whether 68Ga-FL-031 PET imaging, compared with 18F-FDG PET, can detect and stage small cell lung cancer, breast cancer, nasopharyngeal carcinoma and other tumors in adults.

  Recruiting Early Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07301801

• LM-350 treatment for advanced solid tumors

  This trial will test LM-350, an experimental injectable drug, in adults with advanced solid tumors who have not responded to or cannot receive standard treatments.

  Recruiting at 3 sites Phase 1/2 LaNova Medicines Limited · Wollongong, New South Wales and 3 other locations · NCT07112222

• mRNA vaccine targeting KRAS-mutated cancers

  We will try an mRNA vaccine that targets KRAS mutations in adults with KRAS-mutated solid tumors, given alone or with the immunotherapy drug toripalimab and/or standard chemotherapy.

  Recruiting Phase 1 Sichuan University · Chengdu, Sichuan · NCT07004244

• Testing LM-299 for advanced malignant tumors

  This study is testing a new treatment called LM-299 to see if it is safe and can help people with advanced solid tumors that haven't responded to other therapies.

  Recruiting Phase 1/2 LaNova Medicines Limited · Perth, Western Australia and 5 other locations · NCT06650566

• Testing LM-101 Injection for Advanced Malignant Tumors

  This study is testing a new injection called LM-101 to see if it is safe and effective for people with advanced malignant tumors, both on its own and with other treatments.

  Recruiting at 3 sites Phase 1/2 LaNova Medicines Limited · Guangzhou, Guangdong and 4 other locations · NCT05615974

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.